VYNE
VYNE Therapeutics Inc.0.4027
+0.0427+11.9%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
13.40MP/E (TTM)
-Basic EPS (TTM)
-0.79Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
8-K
Nasdaq bid price noncompliance
VYNE Therapeutics received Nasdaq notice on September 11, 2025, for failing to maintain a $1.00 minimum bid price over 30 consecutive days, triggering Item 3.01 disclosure. The stock stays listed on Nasdaq Capital Market with 180 days until March 10, 2026, to hit $1.00 for ten straight trading days and regain compliance. VYNE eyes options like a reverse split, but success isn't assured. Delisting looms if unmet.
8-K
VYNE cuts costs, extends cash
VYNE Therapeutics reported Q2 2025 net loss of $5.8 million, down from $9.4 million last year, thanks to slashed R&D costs from $7.3 million to $4.9 million amid pipeline tweaks. Cash stands at $39.6 million, stretching runway to mid-2027 after cuts. Board shrinks with resignations of Christine Borowski and Anthony Bruno, no disputes cited. VYN202 shows promise in psoriasis trial, but FDA hold lingers on males.
BRNS
Barinthus Biotherapeutics plc
0.74-0.00
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
DYN
Dyne Therapeutics, Inc.
19.55-0.04
FBIO
Fortress Biotech, Inc.
3.51+0.19
IMA
ImageneBio, Inc.
6.25+0.08
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
NKTR
Nektar Therapeutics
49.16-4.14
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
THAR
Tharimmune, Inc.
2.41+0.01